Modality
Radioligand
MOA
MALT1i
Target
CD20
Pathway
Ferroptosis
PVPAHADHD
Development Pipeline
Preclinical
~Sep 2019
→ ~Dec 2020
Phase 1
~Mar 2021
→ ~Jun 2022
Phase 2
Sep 2022
→ Oct 2029
Phase 2Current
NCT05380983
183 pts·PAH
2022-09→2029-10·Completed
183 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-10-073.5y awayPh2 Data· PAH
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P2
Complet…
Catalysts
Ph2 Data
2029-10-07 · 3.5y away
PAH
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05380983 | Phase 2 | PAH | Completed | 183 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| ITC-6153 | Intra-Cellular | Phase 3 | KRASG12C | |
| Gelisertib | Samsung Biologics | Approved | IL-23 |